Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zolbetuximab plus mFOLFOX6 versus placebo plus mFOLFOX6 as first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma
jRCT2080224032Phase 4Completed
- Sponsor
- Astellas Pharma
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 4, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing zolbetuximab + mFOLFOX6 with placebo + mFOLFOX6 (2 arms). Started Sep 2018; status: completed.
02
Drugs
zolbetuximab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2080224032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224032.